Bayer Quarterly Statement Q1 2026
Bayer Group Condensed Consolidated Income Statements

€ million

 

Q1 2025

 

Q1 2026

Net sales

 

13,738

 

13,405

Cost of goods sold

 

(5,625)

 

(5,232)

Gross profit

 

8,113

 

8,173

Selling expenses

 

(3,159)

 

(3,164)

Research and development expenses

 

(1,458)

 

(1,419)

General administration expenses

 

(548)

 

(532)

Other operating income

 

205

 

810

Other operating expenses

 

(829)

 

(340)

EBIT1

 

2,324

 

3,528

Equity-method income (loss)

 

(2)

 

13

Financial income

 

92

 

127

Financial expenses

 

(584)

 

(679)

Financial result

 

(494)

 

(539)

Income before income taxes

 

1,830

 

2,989

Income taxes

 

(526)

 

(222)

Income after income taxes

 

1,304

 

2,767

of which attributable to noncontrolling interest

 

5

 

4

of which attributable to Bayer AG stockholders (net income)

 

1,299

 

2,763

 

 

 

 

 

 

 

 

 

Earnings per share

 

 

 

 

Basic

 

1.32

 

2.81

Diluted

 

1.32

 

2.81

1

For definition see Annual Report 2025, A 2.3 “Alternative Performance Measures Used by the Bayer Group.